Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies
Mark P Chao Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA Abstract: Over the last few decades, advances in immunochemotherapy have led to dramatic improvement in the prognosis of non-Hodgkin’s lymphoma (NHL). Despite these advances, relap...
Main Author: | Chao MP |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-08-01
|
Series: | Cancer Management and Research |
Online Access: | http://www.dovepress.com/treatment-challenges-in-the-management-of-relapsed-or-refractory-non-h-a14143 |
Similar Items
-
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
by: Chen R, et al.
Published: (2015-03-01) -
Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
by: Karantanos T, et al.
Published: (2017-05-01) -
TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01) -
Relapsed and refractory classical Hodgkin lymphoma immunotherapy
by: Kirill Lepik
Published: (2020-10-01) -
Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01)